The present invention relates to a composition for preventing, improving, or treating fragile X syndrome or related developmental disorders, comprising lisuride, a lisuride metabolite, or a pharmaceutically acceptable salt thereof.

The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.

The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.

Disclosed herein are various compositions comprising neoplastic formulations and their methods of use.

Disclosed herein are various compositions comprising neoplastic formulations and their methods of use.

The present inventions provides drug-drug conjugates, drug-porphyrin conjugates, nanoparticles of the conjugates, as well as modified nanoparticles having PEGylated exteriors or encapsulated by red blood cell vesicles. The conjugates, nanoparticles and nanocarriers are useful for treating cancers and other diseases, as well as for imaging diseased tissue or organs.

The present inventions provides drug-drug conjugates, drug-porphyrin conjugates, nanoparticles of the conjugates, as well as modified nanoparticles having PEGylated exteriors or encapsulated by red blood cell vesicles. The conjugates, nanoparticles and nanocarriers are useful for treating cancers and other diseases, as well as for imaging diseased tissue or organs.

New clinical uses of anti-CD127 agents, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer. Methods for treating a patient having a CD127-positive cancer are provided, in particular a CD127-positive leukemia or a CD127-positive solid tumor, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and not having Antibody Dependent Cytotoxic Activity (ADCC), in particular against immune cells, more particularly against T cells.

New clinical uses of anti-CD127 agents, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer. Methods for treating a patient having a CD127-positive cancer are provided, in particular a CD127-positive leukemia or a CD127-positive solid tumor, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and not having Antibody Dependent Cytotoxic Activity (ADCC), in particular against immune cells, more particularly against T cells.

The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent and proliferating cancers cells with DYRK1 inhibitor in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with a MEK inhibitor or a b-RAF inhibitor, or a KRAS inhibitor.